<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03199586</url>
  </required_header>
  <id_info>
    <org_study_id>NP-G2-044-P1-01</org_study_id>
    <nct_id>NCT03199586</nct_id>
  </id_info>
  <brief_title>Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)</brief_title>
  <official_title>First-in-Human, Dose Finding, Open Label Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novita Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Translational Drug Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Novita Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      First-in-human phase 1 study to determine safety of NP-G2-044 when given orally on a daily X
      28 days followed by a 14 day rest period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment related adverse events</measure>
    <time_frame>24 months</time_frame>
    <description>as assessed by CTCAE V4.03</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti tumor activity</measure>
    <time_frame>24 months.</time_frame>
    <description>Resist 1.1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Pancreas Cancer</condition>
  <condition>Prostate Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Colon Cancer</condition>
  <condition>Esophagus Cancer</condition>
  <condition>Liver Cancer</condition>
  <condition>Ovary Cancer</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>NP-G2-044</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NP-G2-044</intervention_name>
    <description>capsule</description>
    <arm_group_label>NP-G2-044</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Disease Related

               -  Patients must have documented history of histologically confirmed solid tumors
                  (as defined by ASCO/CAP guidelines) originating in breast, pancreas, prostate,
                  lung, colon, esophagus, liver, or ovary, and lymphomas, which are locally
                  advanced or metastatic and who are refractory or intolerant beyond primary
                  treatment for their malignancy, or for lymphoma patients who are not eligible for
                  or who have refused autologous or allogenic hematopoietic stem cell transplant

               -  Measurable or evaluable disease documented within one month of the planned
                  protocol treatment (Treatment Period Cycle 1, Day 1)first dose of study drug (PK
                  Period Day 1)

               -  ECOG performance score of 0 and 1

               -  Able to swallow capsules/tablets

        Demographic • Male and females who are 18 years or older

        Laboratory Values

          -  Hemoglobin ≥ 9.0 g/dL

          -  Absolute neutrophil count ≥ 1500/uL

          -  Platelet count ≥ 100,000/uL

          -  Serum creatinine ≤ 1.5 mg/dL or a 24-hour calculated estimated creatinine clearance of
             ≥ 60 mL/min

          -  Serum bilirubin ≤ 1.5 mg/dL

          -  Serum albumin ≥ 3g/dL

          -  AST (SGOT), ALP and ALT (SGPT) ≤ 2.5 times upper limit of normal (OR ≤ 5 times ULN in
             the presence of known liver metastases)

          -  Prothrombin time (PT)/International Normalized Ratio (INR) and partial thromboplastin
             time (PPT) ≤ 1.5 times the upper limit of normal

          -  Serum sodium, potassium, magnesium, calcium and phosphorous levels within
             institutional normal limits; supplements required to maintain normal electrolyte
             levels will be permitted

        Ethical

        • Before any study-specific procedure, the appropriate written informed consent must be
        obtained

        Exclusion Criteria:

        Disease Related

          -  Clinical or radiographical evidence of active brain metastasis

          -  Patients who have not recovered to ≤ grade 1 toxicities except grade 2 alopecia or
             neuropathy associated with previous chemotherapy, radiotherapy, biologic, hormone or
             prior investigational therapies.

        Medications:

          -  Chemotherapy or other cancer, radiation or surgical treatments within 2 weeks or five
             half-lives (whichever is shorter) of the first dose of study drug (PK Period Day 1)
             planned first protocol treatment (i.e., cycle 1 day 1) or not yet recovered from
             respective treatments

          -  Patients who have had allogenic hematopoietic stem cell transplant or allogenic bone
             marrow transplant

          -  Patients who have had prior solid organ transplant

          -  Patients who are on immune suppression drugs or anti-transplant rejection drugs

        General:

          -  History of any medical or psychiatric condition or addictive disorder, or laboratory
             abnormality that in the opinion of the investigator, may increase the risks associated
             with study participation or treatments that may interfere with the conduct of the
             study or the interpretation of study results

          -  Prior history of clinically significant gastrointestinal bleeding, intestinal
             obstruction or gastrointestinal perforation within 6 months before planned initiation
             of study treatment

          -  Uncontrolled diabetes

          -  History of long QT syndrome or clinically significant cardiac arrhythmia, other than
             stable atrial fibrillation

          -  Mean QTcF &gt; 450 msec in men and mean QTcF &gt; 470 msec in women at screening

          -  Myocardial infarction within the previous 6 months before planned initiation of study
             treatment

          -  Active infection requiring intravenous antibiotics within 2 weeks of the first dose of
             study drug (PK Period Day 1) before planned initiation of study treatment

          -  Prior history or current positive tests for hepatitis B, hepatitis C or human
             immunodeficiency virus

          -  Currently enrolled in or has not yet completed at least 30 days since ending other
             investigational device or drug study before planned date of first dose, or the patient
             is currently receiving other investigational agent(s)

          -  Pregnant, planning a pregnancy or breast feeding during the study

          -  Male or female not willing to use adequate contraceptive precautions during the study
             period

          -  Unwilling or unable to comply with study requirements or not available for follow-up
             assessments

          -  Any disorder that compromises the ability of the patient to give written informed
             consent and/or to comply with study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jillian Zhang, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Novita Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachel Condjella, PhD</last_name>
    <phone>602.358.8318</phone>
    <email>rcondjella@td2inc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HonorHealth Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Schaffer, MSN, RN, AOCNS</last_name>
      <phone>480-323-1791</phone>
    </contact>
    <investigator>
      <last_name>Frank Tsai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Hotline Study Number 17345</last_name>
      <phone>877-467-3411</phone>
    </contact>
    <contact_backup>
      <phone>626-218-1133</phone>
    </contact_backup>
    <investigator>
      <last_name>Vincent Chung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann E Sisk</last_name>
      <phone>646-888-4226</phone>
    </contact>
    <investigator>
      <last_name>Komal Jhaveri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2017</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

